Esophagitis

Implantica's RefluxStop™ is now available in seven hospitals in Spain adding two new centers of excellence

Retrieved on: 
星期四, 五月 2, 2024
Certification, PMID, Cancer, Esophagitis, Surgeon, Dysphagia, Patient, Prevalence, Barrett's esophagus, GERD

), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra.
  • More patients in Spain will have access to the innovative RefluxStop™ procedure now, given that a total of seven anti-reflux centers of excellence in the country regularly perform the procedure.
  • "It's a new day we've long awaited in the world of surgical GERD treatment," says Dra.
  • She continues, "I'm pleased to see that RefluxStop does not encircle the food passageway and restores the body's natural physiology.

Koneksa Announces Study with New York Proton Center to Collect Patient-Generated Health Data During Proton Radiotherapy in Lung Cancer

Retrieved on: 
星期四, 四月 25, 2024
Technology, Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Research, Software, Hospitals, Genetics, Health Technology, Science, Data Management, Clinical Trials, Proton, Cancer, Lung cancer, Radiation, Chemoradiotherapy, SCLC, Vital signs, Collection, Carcinoma, Radiation therapy, Dermatitis, Esophagitis, NYPC, Fatigue, CRT, RT, Lung, Biomarker, NSCLC, Medical imaging

Koneksa , a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in a pilot study collecting patient-generated health data (PGHD) during proton radiotherapy for lung cancer in collaboration with the New York Proton Center (NYPC), a leading institution in cancer care and research.

Key Points: 
  • Koneksa , a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in a pilot study collecting patient-generated health data (PGHD) during proton radiotherapy for lung cancer in collaboration with the New York Proton Center (NYPC), a leading institution in cancer care and research.
  • The study, led by principal investigator Nitin Ohri, M.D., a professor in Radiation Oncology at the Montefiore Einstein Comprehensive Cancer Center, aims to demonstrate the feasibility of PGHD collection during proton beam radiotherapy for lung cancer.
  • “This pilot study represents a critical step in leveraging digital health technology to enhance cancer treatment outcomes,” said John Wagner, M.D., Ph.D., Chief Medical Officer, Koneksa.
  • Locally advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are typically treated with definitive thoracic radiotherapy (RT), often in the form of concurrent chemoradiotherapy (CRT).

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
星期二, 三月 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

Global Enteral Feeding Devices Market Insights 2024-2029 with Avanos Medical and B. Braun Melsungen Leading through Substantial R&D Investments - ResearchAndMarkets.com

Retrieved on: 
星期二, 三月 12, 2024
Health, Medical Devices, Other Health, Hospital, Cardiology, Incidence, Enterostomy, Neurology, Conditional sentence, Growth, Prevalence, Obesity, Esophagitis, DSM-IV codes, Patient, Research, GI, Cancer, HEN, Crohn's disease, Ageing, Parenteral nutrition, Syringe, Diet, Gastrointestinal disease, Investment, Malnutrition, Safety, IBS, Dysphagia, USD, Avanos Medical, Tubing (recreation), Pediatrics, PEG

The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.

Key Points: 
  • The enteral feeding devices market features diverse players, from well-established giants to dynamic emerging entities, focusing on innovation and strategic growth.
  • Leading firms such as Avanos Medical and B. Braun Melsungen distinguish themselves through substantial research and development (R&D) investments, forming strategic alliances, and initiatives to increase their market share.
  • The enteral feeding devices market is set for sustained growth, driven by healthcare advancements and a global emphasis on chronic disease management and nutritional support.
  • North America, particularly the United States and Canada, leads in the enteral feeding devices market.

NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation

Retrieved on: 
星期四, 二月 22, 2024
Esophagitis, Tricuspid valve, Denervation, General partnership, Mitral regurgitation, Johnson & Johnson, Mayo Clinic, Clinical professor, Hypertension, Ethicon, Mitral valve, Patient, Disease, Pharmaceutical industry

MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.

Key Points: 
  • MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.
  • The company appointed Todd Berg as Chief Executive Officer to oversee clinical and commercial programs for transeptal and transapical repair of damaged mitral valve chords resulting in regurgitation.
  • Berg has over 30 years of experience successfully developing and commercializing novel medical therapies and holds over 100 U.S. patents.
  • The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling," said Berg.

NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation

Retrieved on: 
星期四, 二月 22, 2024
Esophagitis, Tricuspid valve, Denervation, General partnership, Mitral regurgitation, Johnson & Johnson, Mayo Clinic, Clinical professor, Hypertension, Ethicon, Mitral valve, Patient, Disease, Pharmaceutical industry

MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.

Key Points: 
  • MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.
  • The company appointed Todd Berg as Chief Executive Officer to oversee clinical and commercial programs for transeptal and transapical repair of damaged mitral valve chords resulting in regurgitation.
  • Berg has over 30 years of experience successfully developing and commercializing novel medical therapies and holds over 100 U.S. patents.
  • The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling," said Berg.

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Retrieved on: 
星期二, 二月 13, 2024
Urinary tract infection, Gastroesophageal reflux disease, Research, Heartburn, Toxicity, Magnesium, Polyp, Liver, CYP, CGA, Achlorhydria, Esophagitis, Patient, PBM, Vitamin B12, Vonoprazan, Kidney, Spine, Lactation, Absorption, Hypokalemia, SCAR, Calcium, Express Scripts, TIN, Endoscopy, Tablet, Express, Magnesium deficiency, Hypocalcemia, Diarrhea, Hypersensitivity, Physician, Gastritis, Malabsorption, GERD, PPI, Hypertension, SJS, Enzyme inhibitor, EGFR, Stevens–Johnson syndrome, Indigestion, Nelfinavir, Clostridioides, Abdominal pain, Hip, Pharmacy, Enzyme, Glomus tumor, FDA, CDAD, Atazanavir, Risk, BMJ Open, Wrist, Drug, Impairment, Pharmaceutical industry

Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.

Key Points: 
  • Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.
  • doi:10.1136/ bmjgast-2022-000941
    VOQUEZNA® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated:
    for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD in adults.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.
  • Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR

Sagard Healthcare Announces Closing of Credit Facility and Recent Investment Highlights

Retrieved on: 
星期四, 一月 4, 2024
Biotechnology, Commercial Building & Real Estate, Construction & Property, FDA, Professional Services, Health, Pharmaceutical, Medical Devices, Health Insurance, Asset Management, Finance, US FDA, Professional corporation, Health care, United Therapeutics, Partner, Helicobacter pylori, MannKind Corporation, Therapy, Pulmonary hypertension, Esophagitis, Growth, Investment, Dostarlimab, Orthostatic hypertension

Sagard Healthcare – a biopharmaceutical royalty and credit investor – today announced several developments and milestones for the strategy, including the closing of a $250 million permanent credit facility and the completion of nearly $250 million of new investments.

Key Points: 
  • Sagard Healthcare – a biopharmaceutical royalty and credit investor – today announced several developments and milestones for the strategy, including the closing of a $250 million permanent credit facility and the completion of nearly $250 million of new investments.
  • Sagard Healthcare invests in approved and medically-necessary biopharmaceuticals, medical devices, and diagnostics through royalty monetization, revenue interest financing and secured credit investments.
  • Sagard is pleased to announce that in December 2023, it closed a $250 million revolving credit facility with a syndicate of lenders.
  • The facility is expected to grow in size as Sagard continues to expand its portfolio of royalty and credit investments.

Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn

Retrieved on: 
星期二, 十一月 28, 2023
HIV-1, Risk, Heartburn, MOA, Enzyme inhibitor, Potassium, FDA, Magnesium, Nausea, PPI, Inflammation, Prescription, Esophagus, Bone fracture, Skin, Chills, Extrapyramidal system, Fever, Vitamin, Breast milk, Infection, Diarrhea, Helicobacter pylori, Indigestion, Bleeding, Disease, Muscle weakness, Tongue, Calcium, Acid, University, Human, Pharmacy, Clostridioides, Vonoprazan, Urine, Hip, B-12, Food, Polyp, Esophagitis, GERD, Chronic pain, Blood, Dizziness, Blister, Gastroesophageal reflux disease, Tablet, Vitamin B12, Scar, Patient, Wrist, Medicine, Seizure, HIV, Stomach, Lymph, Allergy, Clostridioides difficile, Rash, Weakness, Urinary tract infection, Hypoesthesia, Week, Myalgia, Spine, Spasm, Kidney, Face, Rilpivirine, Lansoprazole, Pharmaceutical industry

“We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.

Key Points: 
  • “We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said Martin Gilligan, Chief Commercial Officer at Phathom Pharmaceuticals.
  • “Erosive GERD is a highly prevalent condition affecting over 20 million people in the U.S.,3,4 many of whom experience troubling symptoms, including painful heartburn.
  • Phathom is offering programs for eligible patients who face coverage or affordability issues, including co-pay assistance for patients with commercial insurance.
  • for up to 6 months to maintain healing of Erosive Acid Reflux and for relief of heartburn related to Erosive Acid Reflux.

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

Retrieved on: 
星期四, 十一月 9, 2023
FDA, Research, Food, PPI, Vonoprazan, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Heartburn, Helicobacter pylori, Tablet, Clinical trial, Hercules, Commercial, New Drug Application, Enzyme inhibitor, NDA, Safety, Leyland Royal Tiger PSU, PARK, Chemistry, Patient, NERD, Gastroesophageal reflux disease, Esophagitis, State, Pharmaceutical industry, Video game, Bank, GERD

Third Quarter 2023 Financial Results:

Key Points: 
  • Third Quarter 2023 Financial Results:
    Net loss for the third quarter ended September 30, 2023, was $43.2 million, compared to $51.1 million for third quarter 2022.
  • Third quarter 2023 net loss included a non-cash charge related to stock-based compensation of $6.1 million compared to $5.8 million for third quarter 2022.
  • Research and development expenses for the third quarter 2023 were $12.3 million, a decrease of $6.7 million compared to $19.0 million for third quarter 2022.
  • General and administrative expenses for the third quarter 2023 were $23.4 million, a decrease of $0.1 million compared to $23.5 million for third quarter 2022.